Q-omics provides the consensus-scored TRAJ14 profile across patient tissues and cancer cell-line models. TRAJ14 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TRAJ14 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, TRAJ14 RNA expression shows 12,139 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where TRAJ14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ14 survival associations across molecular data types. TRAJ14 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ14 RNA expression–survival associations across cancer types. High TRAJ14 expression shows unfavorable associations in ACC, TGCT, LGG, LIHC and READ, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TRAJ14 RNA expression.
This table summarizes TRAJ14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ14 shows higher tumor expression in KIRC. The KIRC box plot shows higher TRAJ14 RNA expression in tumor versus normal tissue (log2 FC = +0.248, t-test p = .006).
This table shows molecular features associated with TRAJ14 in patient tissues and cancer cell lines. In patient samples, TRAJ14 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
